Kidney Transplantation: Management of Pharmacotherapy, Age, Gender, and Rejection Publisher

Summary: How can transplant teams reduce kidney rejection? A records review recommends tighter immunosuppressant monitoring, but did not test whether this improves outcomes. #KidneyTransplant #Pharmacology

Tolou Ghamari Z
Source: Current Chemical Biology Published:2026

Abstract

Introduction: Due to the need for a combination of drugs after kidney transplantation, the risk of adverse drug reactions is high. This study aims to analyse the age, gender, and pharmacotherapy management of those who were rejected and those who were not during their hospital stay. Methods: In this retrospective survey, medical records of 124 kidney transplants obtained from Isfahan Tertiary Hospital (Khorshid) were evaluated. Data for each kidney transplant recipient included age, gender, donor, preference for vessel anastomosis, evidence of acute tubular necrosis, reported rejection episode, designated medication protocols, and clinical and biochemical variables, which were noted in the database. Results: The mean ± SD of age was 42.3 ± 13.6 years (Min: 16, Max: 70). The incidence of reported acute tubular necrosis versus acute rejection was 21% versus 33%. In those with rejection episodes, thymoglobulin was administered, accompanied by methylprednisolone pulse therapy. Immunosuppressive treatment was mainly based on mycophenolic acid, tacrolimus, and cyclosporine (with brand names associated with different companies). Other drugs such as co-trimoxazole, calcium carbonate, amlodipine, folic acid, ferrous sulfate, omeprazole, clotrimazole, and furosemide were specified in the medical records. Discussion: Many factors, such as economic factors, the knowledge of the health care team, and pharmacotherapy strategies, could influence clinical outcomes after kidney transplantation. A close therapeutic drug monitoring schedule could decrease the rate of acute rejection, graft loss, and death. Conclusion: To improve the quality and quantity of life after kidney transplantation, evidence-based management strategies, including prospective immunosuppressive trough-level (C0) monitoring and its correlation with dose, are recommended. 2026, Bentham Science Publishers